Cofilin 1 是帕金森病血浆细胞外囊泡相关生物标志物
研究通过超速离心分离血浆细胞外囊泡(EV),对帕金森病(PD)患者与健康对照进行蛋白质组学分析,鉴定出 CFL1 等 PD 特异性 EV 蛋白,并用酶联免疫吸附试验验证。EV-CFL1 在 PD 中显著升高(p < 0.0001),诊断曲线下面积 0.87,可区分 PD 与进行性核上性麻痹(曲线下面积 0.914),且水平独立于年龄、疾病分期和运动严重程度。
要点
- EV-CFL1 在 PD 患者血浆中显著升高,诊断曲线下面积 0.87。
- EV-CFL1 可区分 PD 与进行性核上性麻痹,曲线下面积 0.914。
- EV-CFL1 水平独立于年龄、疾病分期和运动严重程度。
核心结论
- EV 相关 CFL1 是 PD 特异性血液标志物,诊断准确性强,可区分 PD 与非典型帕金森综合征。
- CFL1 在人和小鼠 PD 脑组织中检出,其在 PD 脑内的蓄积提示可能参与疾病发病机制。
研究设计与样本
- 研究通过超速离心分离血浆 EV 并进行表征。
- 对 PD 患者与健康对照的总血浆 EV 进行蛋白质组学分析,候选蛋白用酶联免疫吸附试验验证。
- 用受试者工作特征曲线和精确率-召回率曲线分析评估诊断准确性。
- 在进行性核上性麻痹和肌萎缩侧索硬化中检验疾病特异性。
- 在人和小鼠 PD 脑组织中进行组织化学和免疫荧光分析。
主要发现
- 蛋白质组学分析鉴定出 PD 特异性 EV 蛋白,包括 cofilin 1(CFL1),其在 PD 来源 EV 中显著富集。
- EV-CFL1 水平在 PD 中较健康对照显著升高(p < 0.0001)。
- 受试者工作特征分析显示 EV-CFL1 诊断性能强(曲线下面积 0.87)。
- EV-CFL1 水平可区分 PD 与进行性核上性麻痹患者(曲线下面积 0.914)。
- CFL1 富集于 L1 细胞黏附分子阳性 EV,提示可能来源于神经元;EV-CFL1 水平独立于年龄、疾病分期和运动严重程度。
关键数值与推荐
- EV-CFL1 在 PD 与健康对照间差异显著(p < 0.0001)。
- EV-CFL1 诊断 PD 的曲线下面积为 0.87。
- EV-CFL1 区分 PD 与进行性核上性麻痹的曲线下面积为 0.914。
临床怎么用
- EV-CFL1 可作为 PD 的血液基诊断标志物,辅助区分 PD 与非典型帕金森综合征。
- EV-CFL1 水平不受年龄、疾病分期和运动严重程度影响,可能适用于不同疾病阶段的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Parkinson's disease (PD) lacks reliable, minimally invasive biomarkers for diagnosis. This study aimed to identify and validate PD-specific plasma extracellular vesicle (EV)-associated proteins. METHODS: Plasma EVs were isolated by ultracentrifugation and characterized. Proteomic profiling of total plasma EVs from PD patients and healthy controls was performed, and a candidate protein identified after analysis was validated by enzyme-linked immunosorbent assay. Diagnostic accuracy was evaluated using receiver operating characteristic and precision-recall curve analysis. Disease specificity was examined in progressive supranuclear palsy and amyotrophic lateral sclerosis. Histochemical and immunofluorescence analyses were conducted in human and mouse PD brain tissue. RESULTS: Proteomic analysis identified distinct PD-specific EV proteins, including cofilin 1 (CFL1), which was significantly enriched in EVs isolated from PD. EV-CFL1 levels were significantly elevated in PD compared with healthy controls (p < 0.0001). Receiver operating characteristic analysis showed strong diagnostic performance for EV-CFL1 (area under the curve 0.87). Also, EV CFL1 levels could distinguish PD from progressive supranuclear palsy patients (area under the curve 0.914). CFL1 was enriched in L1 cell adhesion molecule-positive EVs, indicating a possible neuronal origin. CFL1 was detected in both human and mouse PD brain sections. Importantly, EV-CFL1 levels were independent of age, disease stage, and motor severity. INTERPRETATION: EV-associated CFL1 represents a PD-specific, blood-based marker with strong diagnostic accuracy and can distinguish PD from atypical parkinsonism. The presence of CFL1 was confirmed in human and mouse PD brain tissue, and its accumulation in PD brain suggests a possible role in disease pathogenesis. ANN NEUROL 2026.
引用
- Chandran D, Agrawal U, Damayanthi D, et al. Cofilin 1 Is an Extracellular Vesicle-Associated Plasma Biomarker of Parkinson's Disease in Humans. Ann Neurol. 2026. PMID: 42677823. doi:10.1002/ana.78348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。